You are here

About | ALK Testing

A Video Introduction to

Click here for a video explaining the purpose and contents of is an educational website for healthcare providers to learn about testing for ALK in non-small cell lung cancer.

ALK gene rearrangement occurs in 3 to 5 percent of non-small cell lung cancers, acting as an oncogenic driver in these exists to inform oncologists and pathologists on why, who, when, where and how to test for ALK.

ALK-positivity can be detected using several methods, including:

  • Fluorescence in-situ hybridisation
  • Immunohistochemistry
  • Reverse transcription-polymerase chain reaction
  • And next-generation sequencing.

According to international guidelines, ALK testing should be carried out systematically in all advanced non-squamous non-small cell lung cancer patients. Clinico-pathological features should not be used to select patients for testing.

To inform rapid treatment decisions, all advanced non-small cell lung cancer patients should be tested for ALK at initial diagnosis, allowing patients to receive the most appropriate treatment.

Sequential testing for EGFR and ALK may delay treatment therefore it is preferable to test for all relevant molecular markers in parallel...

...and the guidelines state that molecular test results should be available within 10 working days of receiving the specimen in the testing laboratory.

At, you will find a number of tools and resources to help facilitate the routine, rapid and accurate testing for ALK. These include videos of expert opinion, links to useful publications, an interactive training module on ALK testing and a searchable map where you can find your local ALK testing centre.

Come in to to learn more about identifying ALK-positivity in patients with non-small cell lung cancer.